PharmacoEconomics & Outcomes News

, Volume 803, Issue 1, pp 5–5 | Cite as

Avibactam/ceftazidime cost effective for abdominal infections

Clinical study
  • 4 Downloads

References

  1. 1.
    Tichy E, et al. Cost-effectiveness analysis of ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to meropenem for complicated intra-abdominal infection (cIAI) . 28th European Congress of Clinical Microbiology and Infectious Diseases : (plus poster) abstr. E0056, 21 Apr 2018. Available from: URL: http://www.eccmidlive.org/#resources/cost-effectiveness-analysis-of-ceftazidime-avibactam-caz-avi-as-empirical-treatment-comparing-to-meropenem-for-complicated-intra-abdominal-infection-ciai.
  2. 2.
    Kongnakorn T, et al. Cost-effectiveness analysis of ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam for complicated intra-abdominal infection (cIAI) . 28th European Congress of Clinical Microbiology and Infectious Diseases : (plus poster) abstr. E0057, 21 Apr 2018. Available from: URL: http://www.eccmidlive.org/#resources/cost-effectiveness-analysis-of-ceftazidime-avibactam-caz-avi-as-empirical-treatment-comparing-to-ceftolozane-tazobactam-for-complicated-intra-abdominal-infection-ciai.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations